Perceptive

Perceptive is a global technology-enabled service provider for preclinical and clinical trial imaging and for interactive response technology (IRT) and randomized trial supply management (RTSM). The company supports pharmaceutical, biotechnology and clinical research organisations across the R&D lifecycle, from discovery through to regulatory submission. It was formed in September 2024 from the merger and rebrand of Calyx and Invicro under a single identity, and reports more than 50 years of combined specialised experience in the clinical research industry.

Its work is organised into three units. Perceptive Discovery provides preclinical and translational imaging, including radiochemistry and in vivo imaging. Perceptive eClinical offers cloud-based randomisation and trial supply management platforms alongside electronic clinical outcome assessments (eCOA). Perceptive Imaging operates an independent imaging core laboratory for clinical trials worldwide. Technical coverage spans clinical, preclinical and translational imaging, radiopharmaceutical therapy imaging and imaging core laboratory services.

The company reports having supported nearly 12,000 clinical trials and more than 800 regulatory approvals, and operates a 24/7 service delivery model. It serves most of the world's leading pharmaceutical and biotechnology companies, as well as CROs, across therapeutic areas including oncology, neuroscience, radiopharmaceutical therapy and rare diseases.

Perceptive delivers services across the US, Europe, the UK and Asia. It maintains embedded clinical and imaging centres at Imperial College London and Barts Cancer Institute, which provide first-in-human imaging capabilities. Engineering and technology leadership roles touch its cloud-based randomisation platforms, imaging core laboratory systems and eCOA products.